Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai Lifesciences Holdings Inc. (MRVI) provides essential tools for breakthrough therapies and diagnostics through its nucleic acid production and biologics safety testing solutions. This news hub offers investors and industry professionals direct access to verified updates about the company's scientific advancements and strategic developments.
Track MRVI's latest financial results, manufacturing innovations, and partnership announcements in one centralized location. Our curated news collection helps stakeholders monitor regulatory milestones, technology licensing agreements, and capacity expansion initiatives critical to the life sciences sector.
Key updates include earnings disclosures, facility certifications, reagent production scaling efforts, and quality control advancements. Users will find information about Maravai's GMP-grade oligonucleotides, CLIA-certified testing services, and contributions to cell/gene therapy development pipelines.
Bookmark this page for real-time access to Maravai's progress in enabling precision medicine and vaccine development. Check regularly for objective reporting on their role in supporting biopharmaceutical research and diagnostic innovation worldwide.
Maravai LifeSciences (NASDAQ: MRVI) has acquired MyChem for $240 million in cash, with potential additional payments based on performance. This strategic acquisition enhances Maravai’s offerings in the rapidly growing cell and gene therapy market by integrating MyChem’s ultra-pure nucleotides used in mRNA synthesis. The deal aims to accelerate innovation and growth within Maravai's Nucleic Acid Production segment, with MyChem's team joining Maravai's operations. Both companies expect synergies and cross-selling opportunities, expanding product offerings to the therapeutics and vaccine sectors.
Maravai LifeSciences (NASDAQ: MRVI) will host an Investor R&D Day on January 28, 2022, featuring insights into its business and market opportunities. The event will include presentations from executives and a panel on trends in cell and gene therapies. Interested parties can view the live webcast on the company's website. Additionally, Maravai will announce its Q4 2021 results on February 23, 2022, followed by a conference call at 2:00 p.m. PT. Participants can access the call via dial-in or the company’s website.
Maravai LifeSciences (NASDAQ: MRVI) announced a successful repricing of its existing credit facilities, expected to yield approximately $6.8 million in annual interest savings. This strategic move strengthens the company's financial foundation, driven by strong cash flows and recent ratings upgrades. The repricing will reduce annual cash interest expenses on term loans, while the maturity dates of the loans remain unchanged. The company's focus on providing life science reagents and services underlines its commitment to supporting biopharmaceutical and diagnostic advancements.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has announced its first Investor R&D Day, set for January 28, 2022, from 9:00 a.m. to 11:30 a.m. Pacific Time. This virtual event aims to provide insights into its life science reagents and services, primarily for biotechnology and pharmaceutical innovations. Attendees can pre-register for the event, and a playback will be available afterward. Maravai continues to be a leader in providing products for drug therapies, diagnostics, and novel vaccines.
Maravai LifeSciences Holdings (NASDAQ: MRVI) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This key index tracks the performance of biotechnology and pharmaceutical companies listed on Nasdaq, reflecting their market activity. To qualify, companies must meet specific criteria such as market capitalization and trading volume. Maravai, a provider of life science reagents and services supporting drug development and diagnostics, demonstrates its growth potential through this milestone.
Maravai LifeSciences (NASDAQ: MRVI) reported a significant 133% revenue increase, reaching $204.8 million for Q3 2021, compared to $87.9 million in Q3 2020. Net income surged 240% to $132.8 million. The company raised its 2021 revenue guidance to $770-$780 million and introduced preliminary 2022 guidance of $840-$880 million. Key growth was driven by Nucleic Acid Production, up 170% year-over-year. Maravai also closed the sale of its Protein Detection segment and published its inaugural Environmental, Social and Governance Report.
On November 8, 2021, New England Biolabs (NEB) announced the release of the HiScribe T7 mRNA Kit featuring TriLink's CleanCap Reagent AG. This new kit simplifies mRNA synthesis, offering high yields with a Cap 1 structure, enhancing biological activity while reducing immunogenicity. NEB's kits are scalable for therapeutic mRNA manufacturing, including vaccine production. The collaboration aims to accelerate research and development in mRNA technology. NEB continues to expand its offerings in molecular biology, supporting global vaccine programs.
Maravai LifeSciences (NASDAQ: MRVI) has announced its participation in two upcoming virtual investor conferences in November 2021. CFO Kevin Herde will engage in a fireside chat at the Stifel Healthcare Conference on November 17 at 10:20 a.m. PT and present at the Nasdaq Investor Conference on November 30 at 7:00 a.m. PT. Live webcasts will be available on the company's investor relations website, with archived versions posted shortly after each event. Maravai specializes in life science reagents and services, supporting drug therapy and diagnostics development.
Maravai LifeSciences (NASDAQ: MRVI) will announce its third quarter 2021 financial results after market close on November 10, 2021. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET the same day, which can be accessed by dialing (833) 693-0536 or (661) 407-1576 with conference ID 9136747. Participants can also listen via live or archived webcast on the company's Investors website. Maravai provides essential products for drug therapy, diagnostics, and vaccine development.
FAQ
What is the current stock price of Maravai Lifesciences Holdings (MRVI)?
What is the market cap of Maravai Lifesciences Holdings (MRVI)?
